CN103237548A - A2b腺苷受体拮抗剂用于治疗肺高血压的应用 - Google Patents

A2b腺苷受体拮抗剂用于治疗肺高血压的应用 Download PDF

Info

Publication number
CN103237548A
CN103237548A CN2011800417298A CN201180041729A CN103237548A CN 103237548 A CN103237548 A CN 103237548A CN 2011800417298 A CN2011800417298 A CN 2011800417298A CN 201180041729 A CN201180041729 A CN 201180041729A CN 103237548 A CN103237548 A CN 103237548A
Authority
CN
China
Prior art keywords
methyl
diketone
pyrazoles
optional replacement
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800417298A
Other languages
English (en)
Chinese (zh)
Inventor
路易斯·贝拉尔迪内利
曾德婉
钟鸿雁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CN103237548A publication Critical patent/CN103237548A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011800417298A 2010-06-30 2011-06-29 A2b腺苷受体拮抗剂用于治疗肺高血压的应用 Pending CN103237548A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36028910P 2010-06-30 2010-06-30
US61/360,289 2010-06-30
PCT/US2011/042379 WO2012003220A1 (en) 2010-06-30 2011-06-29 Use of a2b adenosine receptor antagonists for treating pulmonary hypertension

Publications (1)

Publication Number Publication Date
CN103237548A true CN103237548A (zh) 2013-08-07

Family

ID=44343985

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800417298A Pending CN103237548A (zh) 2010-06-30 2011-06-29 A2b腺苷受体拮抗剂用于治疗肺高血压的应用

Country Status (11)

Country Link
US (1) US20120003329A1 (https=)
EP (1) EP2595630A1 (https=)
JP (1) JP2013533882A (https=)
KR (1) KR20130088834A (https=)
CN (1) CN103237548A (https=)
AU (1) AU2011271510A1 (https=)
BR (1) BR112012032766A2 (https=)
CA (1) CA2802891A1 (https=)
EA (1) EA201291274A1 (https=)
MX (1) MX2012015112A (https=)
WO (1) WO2012003220A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112218867A (zh) * 2018-03-05 2021-01-12 泰昂治疗公司 腺苷受体拮抗剂及其用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
JP2017048116A (ja) * 2014-01-10 2017-03-09 国立研究開発法人国立国際医療研究センター 肺高血圧症治療薬
WO2019157337A1 (en) * 2018-02-08 2019-08-15 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
WO2022187649A1 (en) * 2021-03-05 2022-09-09 Tosk, Inc. Uridine phosphorylase inhibitors to prevent or treat drug-induced pulmonary dysfunction

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1564688A (zh) * 2001-09-06 2005-01-12 拜奥根Idec马萨诸塞公司 治疗肺疾病的方法
CN1585769A (zh) * 2001-11-09 2005-02-23 Cv医药有限公司 A2b腺苷受体拮抗剂
CN101039677A (zh) * 2004-10-15 2007-09-19 Cv医药有限公司 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法
US20080045549A1 (en) * 2006-06-29 2008-02-21 Pier Giovanni Baraldi Adenosine a2b receptor antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
DE60206756T2 (de) 2001-06-29 2006-07-13 CV Therapeutics, Inc., Palo Alto Purin derivate als a2b adenosin rezeptor antagonisten
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
DE10303639B4 (de) 2003-01-30 2016-05-25 Zf Friedrichshafen Ag Vorrichtung zur Steuerung einer hydraulisch betätigbaren Kupplung eines Automatgetriebes
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
US7601723B2 (en) * 2005-02-25 2009-10-13 Pgx Health, Llc Pyridyl substituted xanthines
EP1891070A1 (en) 2005-06-16 2008-02-27 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP2101777B1 (en) * 2006-12-12 2015-05-20 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
EP2268641B1 (en) 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1564688A (zh) * 2001-09-06 2005-01-12 拜奥根Idec马萨诸塞公司 治疗肺疾病的方法
CN1585769A (zh) * 2001-11-09 2005-02-23 Cv医药有限公司 A2b腺苷受体拮抗剂
CN101039677A (zh) * 2004-10-15 2007-09-19 Cv医药有限公司 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法
US20080045549A1 (en) * 2006-06-29 2008-02-21 Pier Giovanni Baraldi Adenosine a2b receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王溱 等: "《X线诊断学》", 30 June 1994, 河北教育出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112218867A (zh) * 2018-03-05 2021-01-12 泰昂治疗公司 腺苷受体拮抗剂及其用途
CN112218867B (zh) * 2018-03-05 2023-11-21 泰昂治疗公司 腺苷受体拮抗剂及其用途

Also Published As

Publication number Publication date
WO2012003220A1 (en) 2012-01-05
KR20130088834A (ko) 2013-08-08
AU2011271510A1 (en) 2013-01-10
CA2802891A1 (en) 2012-01-05
EA201291274A1 (ru) 2013-12-30
EP2595630A1 (en) 2013-05-29
MX2012015112A (es) 2013-05-28
US20120003329A1 (en) 2012-01-05
JP2013533882A (ja) 2013-08-29
BR112012032766A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
RU2457842C2 (ru) Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b
ES2959419T3 (es) Formulaciones secas por aspersión
RU2374247C2 (ru) Способ получения антагонистов аденозиновых рецепторов a2b и промежуточные продукты
CN103458690B (zh) 治疗肺动脉高压的组合物和方法
ES2675720T3 (es) Inhibidores de quinasa no selectivos
JP2012056965A (ja) Ａ２ｂアデノシン受容体アンタゴニストを使用した、気道のリモデリングおよび肺の炎症の予防および処置の方法
CN103237548A (zh) A2b腺苷受体拮抗剂用于治疗肺高血压的应用
KR20180100651A (ko) 만성 기침의 치료를 위한 오베피탄트
AU2012254057B2 (en) Use of A2B adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
CN101043889B (zh) A2b腺苷受体拮抗剂在制备促使伤口愈合的药物中的应用
HK40036372A (en) Spray dry formulations
EA050167B1 (ru) Комбинированная терапия, включающая ингибитор пути jak и ингибитор rock

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130807